Addressing the Challenges of Therapeutic Vector Development

Tuesday, November 7, 2017

8:00 am PT, 11:00 am ET, 17:00 CET

The dynamic landscape of molecular biology has bolstered gene therapy endeavors, underscoring their true therapeutic potential in recent years. Investigators have come to realize that gene therapy is only as good as the vectors employed to deliver the molecular payload. For many researchers, vector development is a common yet laborious practice, often without much thought to how the process may affect more important downstream applications. In this GEN webinar, we will discuss factors that are critical for viral vector development from the analytical scale to larger clinical scale manufacturing modalities. Drawing attention to these parameters will ultimately lead to better downstream transductions for gene expression and knockdowns or genome editing.

Boris Kantor, Ph.D.
Assistant Professor and Viral Vector Core Director
Duke University
Johannes C. M. van der Loo, Ph.D.
Director, Clinical Vector Core
The Children’s Hospital of Philadelphia
Miguel Dominguez, M.S.
Global Distribution Manager
Mirus Bio LLC

Registration details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)